US46583P1021 - Common Stock
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the...
Iveric Bio (ISEE) ticked up 0.8% in after hours trading after saying it expects its sale to Astellas (ALPMF) to close on July 11
Iveric Bio (ISEE), which agreed to be acquired by Astellas Pharmaceuticals (ALPMF) in May for $5.9 billion, dropped as much as 8.8%, though it has now pared the loss to 3%
Iveric Bio (ISEE) rose 2.2% after the HSR waiting period for its planned sale to Astellas Pharmaceuticals (ALPMY) expired
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Iveric Bio (ISEE) rose 2% after the shareholder vote for its planned sale to Astellas Pharmaceuticals (ALPMY) was set for July 6. The July 6 date was disclosed in a proxy filing earlier...
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
By David Willey, Benzinga
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IVERIC bio, Inc....
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
These three biotech stocks were on the volatile side today.
The company is working on a treatment for the eye disease known as geographic atrophy.
Apellis Pharmaceuticals (APLS) stock weakness, down 7.1% in premarket trading, is a buying opportunity after competitor Iveric Bio (ISEE) agreed to be sold to Astellas Pharma (ALPMF)...
Apellis Pharmaceuticals (APLS) stock weakness, down 7.1% in premarket trading, is a buying opportunity after competitor Iveric Bio (ISEE) agreed to be sold to Astellas Pharma (ALPMF)...